Skip to main content
Fig. 4 | Alzheimer's Research & Therapy

Fig. 4

From: Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer’s disease tau

Fig. 4

Correlation analysis of metabolic function and end point tau assessments: The end point tau burden and the number of CP13-positive neurons per unit area in the frontal cortex had strong negative correlations with end point findings (a, e) and longitudinal changes (c, g) of normalized FDG uptake in hTau mice. Corresponding plots for the hippocampus indicate the same negative correlation between tau burden and region-specific relative glucose metabolism (b, d, f, h). Purple trendlines show the linear association within the hTau treatment group, whereas the gray trendline provides the linear association for the hTau vehicle group. The dashed black line illustrates the linear association of combined hTau mice. Associated R2 values are indicated in the same color. Solid and dotted lines of non-carrier controls show mean ± SEM

Back to article page